Sorivudine: A Potent Inhibitor of Varicella Zoster Virus Replication

  • Richard J. Whitley
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Effective antiviral therapy has been achieved with the administration of nucleoside analogs, particularly for herpesvirus and human immunodeficiency virus infection. Compounds such as acyclovir, ganciclovir, and penciclovir are prototype nucleoside analogs which have demonstrated antiviral activity against several members of the herpesvirus family. Sorivudine (bromovinyl arabinosyl uracil; BVarak) is a relatively new nucleoside analog which was synthesized by Dr. Machida of the Yamasa Shoyu Company in Japan.1,2 Sorivudine has undergone field trial evaluation for the treatment of zoster in Japanese volunteers and was licensed for the treatment of this disease in 1994 in that country. Currently, the compound is under evaluation in the United States, Canada, Europe, and Australia for the treatment of varicella zoster virus (VZV) infections in both the normal and immunocompromised host. This review will briefly summarize published data on sorivudine and its potential as a therapeutic for VZV infections.

Keywords

Human Immunodeficiency Virus Herpes Zoster Thymidine Kinase Varicella Zoster Virus Nucleoside Analog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Machida H., Sakata S, Kuninaka A. Yoshino H. Antiherpesviral and anticellular effects of 1-b-Darabinofuranosyl-E-5-(2-halogenovinyl) uracil. Antimicrob Agents Chemother. 1981; 20: 47–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Machida H, Sakata S. In vitro and in vivo antiviral activity of 1-b-D-arabinofuranosy-E-5-(2-bromovinyl) uracil ( BV-araU) and related compounds. Antiviral Res. 1984; 4: 135–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Machida H. Comparison of susceptibilities of varicella-zoster virus and herpes simplex virus to nucleoside analogs. Antimicrob Agents Chemother. 1986; 29: 524–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Suzutani T, Machida H, Saktuna T, Azuma M. Effects of various nucelosides on antiviral activity and metabolism of 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1988; 32: 1547–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Cheng, Y-C, Dutschman G, Fox JJ, Watanabe KA, Machida H. Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother. 1981; 20: 420–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Yokota T, Kono K, Mori S, Shigeta S, Kumagai M, Watanabe Y, Machida H. Mechanism of selective inhibition of varicella-zoster virus replication by 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil. A report from Yamasa Shoyu Co., Japan, 1988Google Scholar
  7. 7.
    Soike KF, Baskin G, Cantrell C, Gerone P. Investigation of antiviral activity of 1-b-Darabinofuranosylthymine (ara-T) and 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (BV-araU) in monkeys infected with simian varicella virus. Antiviral Res. 1984; 4: 245–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Whitley RJ, Weiss H, Gnann J, et al. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV-infected patients: Results of a multi-center controlled trial. Presented at the Clinical Research Meeting. San Diego, CA, May 5–8, 1995. J Invest Med 1995; 43: A114.Google Scholar
  9. 9.
    Wallace MR, Sawyer MH, Chamberlin CJ, Hawkins J, Oldfield III EC. BV-aru-U for the treatment of adult varicella. Presented at the Second International Conference on Varicella Zoster Virus Infections. Paris, France. 1994, July 7 and 8.Google Scholar
  10. 10.
    DeHertog D, et al. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV-infected patients: Results of a multi-center controlled trial. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida, October 4–7, 1994. Late breaker.Google Scholar
  11. 11.
    Yawata M. Deaths due to drug interaction. Lancet 1993; 342: 1166.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Richard J. Whitley

There are no affiliations available

Personalised recommendations